The DEA Could Reclassify Cannabis To A Less Restrictive Category
October 20, 2024
A drug policy expert weighs the pros and cons of reclassifying marijuana
A drug policy expert weighs the pros and cons of reclassifying marijuana
“The scientific evidence in favor of removing cannabis from Schedule I remains overwhelming.”
Plaintiffs included “independent operators in Massachusetts who have suffered significant harm and business challenges due to federal prohibition.”
“The risks to the public health posed by marijuana are low compared to other drugs of abuse,” such as benzodiazepines — a Schedule IV drug, or alcohol, which is unscheduled.
The Resource Center for Cannabis and Cannabinoid Research could end up part of a university, nonprofit, or even faith-based organization
“Federal criminalization of safe, regulated intrastate cannabis legal in 38 states is unconstitutional—and unfair to small businesses”
Focused on interstate commerce, new report shows “how to federally legalize cannabis without violating the Constitution or undermining equity and justice”
“Section 280E hampers companies striving to make cannabis accessible for consumers and medical cannabis patients in all legal states.”
